Abstract
Heparin-induced thrombocytopenia (HIT) is a serious complication of heparin treatment, associated with morbidity and mortality. HIT is characterized by thrombocytopenia and thrombotic complications secondary to the formation of antibodies (Abs) against heparin-platelet-factor 4 (PF4) complexes. The pathologic mechanism involves the binding of the heparin-immune-complex to the platelet-Fc-receptor, resulting in platelet activation, aggregation, and rapid elimination. The diagnosis of HIT requires laboratory confirmation. Common laboratory testing is based on immune detection of antibodies directed against the PF4/heparin complex (ID-H/PF4-PaGIA or ELISA). However, these assays suffer from methodological limitations, especially low specificity, as compared to the platelet functional assays. The “gold standard” functional test for detecting of platelet-activating antibodies is the radioactive [14C] serotonin-release assay (14C-SRA) (Sheridan D, et al, Blood. 1986;67:27-30, Kelton JG, et al.,Blood.1988;72:925-30). However, the assay includes the use of a radiolabeled biological probe and requires considerable expertise to obtain reliable results. Consequently, its use is limited to research laboratories.
To overcome the methodological limitations associated with current assays, we modified a functional flow-cytometry assay (FCA), which exhibits high sensitivity and specificity (Tomer, A. Br J Haematol, 1997;98: 648-656 , Tomer, A., et al, Am J Hematol, 1999;61: 53-61). This assay, similar in concept to the 14C-SRA, determines the capacity of the patient's serum to activate platelets in the presence of heparin, using a fluorescent probe.
Consecutive samples from 254 patients clinically suspected for HIT were tested. The FCA assay was compared with the standard ID-H/PF4-PaGIA antigenic assay (DiaMed, Switzerland) with two dilutions to assess specificity (Nellen, V., et al.,Haematologica, 2012;97: 89-97).
Of the total 254 samples tested, 48 (19%) were positive by PaGIA, compared to 13 (5.1%) positive by the functional FCA (Table 1). The number of PaGIA positive samples was reduced to 24 (9.4%) by 1:16 dilution, and to 14 (5.5%) by 1:32 dilution. All FCA positive samples were positive at all PaGIA dilutions (relative sensitivity 93%). Thirty PaGIA negative samples were all negative by the FCA (relative specificity 100%).
The results suggest that the functional FCA is a practical, sensitive, and highly specific test for the reliable diagnosis of HIT.
PaGIA 1:32 dilution . | PaGIA 1:16 dilution . | PaGIA No dilution . | . | . |
---|---|---|---|---|
HIT Positive | HIT Positive | HIT Positive | ||
14 (5.5%) | 24 (9.4%) | 48 (19%) | HIT suspected patients n=254 | |
13 (92.9%) | 13 (54.2%) | 13 (27%) | positive | FCA n=48 |
1 | 11 | 35 | negative |
PaGIA 1:32 dilution . | PaGIA 1:16 dilution . | PaGIA No dilution . | . | . |
---|---|---|---|---|
HIT Positive | HIT Positive | HIT Positive | ||
14 (5.5%) | 24 (9.4%) | 48 (19%) | HIT suspected patients n=254 | |
13 (92.9%) | 13 (54.2%) | 13 (27%) | positive | FCA n=48 |
1 | 11 | 35 | negative |
No relevant conflicts of interest to declare.
Author notes
Asterisk with author names denotes non-ASH members.